Recent Advances in Vaccine Adjuvants: From Lab to Clinic

Adjuvants are critical components in modern vaccines, designed to enhance, modulate, and prolong immune responses to antigens. Over the decades, their evolution from conventional agents like aluminum salts to advanced nanocarrier-based systems has significantly improved vaccine efficacy and broadened their protective capabilities. This review highlights synthesizing the recent landscape of vaccine adjuvants, encompassing their physicochemical properties, immunostimulatory mechanisms, and classification. Key focus areas include traditional adjuvants and emerging materials such as chitosan, alginate, hyaluronic acid, and β-glucans, along with next-generation platforms like lipid nanoparticles, nanoemulsion, virosomes, and proteosomes. We critically examine their roles in antigen delivery and immune system modulation, drawing insights from recent preclinical and clinical developments. In this review, particular focus is placed on formulation design, stability, and scalability, as these attributes are essential for translating adjuvant technologies from laboratory research to clinical application and large-scale manufacturing. Regulatory perspectives and harmonization challenges are also discussed, positioning adjuvant development within the broader framework of pharmaceutical science. Furthermore, the review addresses the safety, tolerability, and regulatory status of clinically approved adjuvants alongside ongoing clinical trials and translational challenges. Emerging strategies such as electroporation, gene gun delivery, and self-assembling peptide systems are also discussed, highlighting innovations driving the next wave of vaccine technologies. By bridging foundational knowledge with recent advances, this review underscores the pivotal role of adjuvant science in shaping the future of global immunization strategies.